Schedule (month number) | 0 | 1 | 3 | 6 | 12 |
---|---|---|---|---|---|
Informed consent | x | Â | Â | Â | Â |
Allocation | x | Â | Â | Â | Â |
Intervention | x | Â | Â | Â | Â |
Aim 1: Retention and adherence (viral load [VL] < 1000 copies/ml) at 12 months | |||||
 Retention in care (data abstraction from facility records) |  | x | x | x | x |
 Viral suppression (VL < 1000 copies/ml) |  |  |  | x | x |
Aim 1b: Behavioral adherence | |||||
 | x | x | x | x | |
 ART side effects |  | x | x | x | x |
 Pharmacy refill data abstraction [68] |  | x | x | x | x |
 Tenofovir diphosphate level |  |  |  |  | x |
Aim 1c: Knowledge and psychosocial impact | |||||
 HIV/ART knowledge and attitudes survey [69] | x |  | x |  | x |
x | x | Â | x | x | |
 Motivation and behavior skills assessment: LifeWindows tool [72] |  | x |  | x | x |
 Self-reported partner disclosure and World Health Organization intimate partner violence survey [73] | x | x |  | x | x |
 Multidimensional Scale of Perceived Social Support (MSPSS) [74] and self-reporting questionnaire [75] | x | x |  | x | x |
 Shortened Alcohol Use Disorders Identification Test [76] and Drug Use Disorders Identification Test [77] | x | x |  | x | x |
 | x |  |  | x | |
Aim 2: Implementation outcomes | |||||
 Participant satisfaction surveys | x |  |  |  |  |
 Interviews with participants, partners, health care workers | x | x | x | x | x |
 Trial fidelity evaluations | x |  |  |  |  |
 Contamination assessment |  | x |  | x | x |
 Time-motion assessments in line with Suggested Time And Motion Procedures (STAMP) checklist [80] | x |  |  |  |  |
Aim 3: Cost-effectiveness analysis. Data collected throughout trial period. Start-up: video creation, training, tablets and accessories (security cable, power bank). Recurring: tablet maintenance; personnel time and salaries |